Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 7/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4338557 | 1.00 | ADAM17 (0.50) | ADAM17SIGMAR1CHRM1CTDSP1HTR2C | |
| SCHEMBL13914852 | 1.00 | ADAM17 (0.50) | ADAM17SIGMAR1CHRM1CTDSP1HTR2C | |
| SCHEMBL4338559 | 1.00 | ADAM17 (0.50) | ADAM17SIGMAR1CHRM1CTDSP1HTR2C | |
| SCHEMBL15754696 | 0.84 | CHRM1 (0.56) | ADAM17SIGMAR1CHRM1HTR2C | |
| SCHEMBL15754695 | 0.84 | CHRM1 (0.56) | ADAM17SIGMAR1CHRM1HTR2C | |
| SCHEMBL28885376 | 0.81 | SLC6A3 (0.44) | ADAM17CTDSP1 | |
| SCHEMBL19335069 | 0.79 | SIGMAR1 (0.43) | ADAM17SIGMAR1CHRM1HTR2C | |
| SCHEMBL20747777 | 0.74 | ADAM17 (0.52) | ADAM17SIGMAR1HTR2C | |
| SCHEMBL13733533 | 0.72 | ADAM17 (0.48) | ADAM17SIGMAR1HTR2C | |
| SCHEMBL13733793 | 0.72 | ADAM17 (0.48) | ADAM17SIGMAR1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244201-A1 | Cyclopropanes with central nervous system activity | NIH-DEITR | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244201-A1 | Cyclopropanes with central nervous system activity | PMP22, CNR1, CNR2 | ADAM17 3138/4885SIGMAR1 690/4885CHRM1 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.